[HTML] sciencedirect.com

[HTML][HTML] Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng… - International Journal of …, 2022 - Elsevier
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …
被引用次数：31 相关文章
[HTML] nih.gov

[HTML][HTML] Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng… - … Journal of Infectious …, 2022 - ncbi.nlm.nih.gov
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng, S Rasmussen… - 2022 - pubmed.ncbi.nlm.nih.gov
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …
[HTML] europepmc.org

[HTML][HTML] Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng, S Rasmussen… - 2021 - europepmc.org
Background Data show that a single dose of casirivimab and imdevimab (REGEN-COV®) is
effective in treating hospitalized individuals and outpatients with COVID-19 and in post …

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.

F Isa, E Forleo-Neto, J Meyer, W Zheng, S Rasmussen… - 2022 - cabidigitallibrary.org
Abstract Objectives: A phase 1, double-blind, placebo-controlled trial was conducted to
evaluate the safety, tolerability, and exploratory efficacy of repeat monthly doses of …

Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng, S Rasmussen… - medRxiv, 2021 - medrxiv.org
Background Data show that a single dose of casirivimab and imdevimab (REGEN-COV®) is
effective in treating hospitalized individuals and outpatients with COVID-19 and in post …

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng… - International Journal of …, 2022 - ijidonline.com
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …
[HTML] medrxiv.org

[HTML][HTML] Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19

F Isa, E Forleo-Neto, J Meyer, W Zheng, S Rasmussen… - medRxiv, 2021 - medrxiv.org
Background Data show that a single dose of casirivimab and imdevimab (REGEN-COV®) is
effective in treating hospitalized individuals and outpatients with COVID-19 and in post …

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.

F Isa, E Forleo-Neto, J Meyer, W Zheng… - … Journal of Infectious …, 2022 - europepmc.org
Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …